Semax Low Dose

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). Unlike intact ACTH, it lacks corticotropic activity and does not stimulate cortisol or adrenal hormone secretion.

Its best-replicated molecular action is rapid upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in hippocampal tissue. Rodent studies document that a single intranasal dose near 50 mcg/kg can triple hippocampal BDNF mRNA within hours, supporting synaptic plasticity and neuronal survival.

Semax also activates serotonergic neurotransmission. Intraperitoneal administration at 0.15 mg/kg increased striatal extracellular 5-hydroxyindoleacetic acid (5-HIAA, the primary serotonin metabolite) by up to 180% within one to four hours in rats, indicating enhanced serotonin turnover rather than direct receptor agonism. This serotonin effect is considered a plausible contributor to the anxiolytic-like activity observed in stressed-animal models.

Additional mechanisms include partial activity at melanocortin receptors MC4 and MC5, expressed in limbic regions involved in stress signaling and inflammatory regulation. Semax also inhibits enkephalin-degrading enzymes in human serum at an IC50 near 10 μM, potentially prolonging the synaptic availability of endogenous opioid peptides.

At the genomic level, transcriptomic analysis in ischemia-reperfusion rat models showed Semax upregulated neurotransmission-related genes (including Drd2 and Gabra5) and suppressed inflammatory mediators (JNK phosphorylation, MMP-9, c-Fos), with 394 differentially expressed genes at a greater than 1.5-fold threshold.

Human evidence for Semax originates almost entirely from Russian clinical studies, most published in Russian-language journals in the 1990s and 2000s. Controls were limited and formal blinding was often absent; no Western regulatory body has reviewed this body of evidence. These limitations require that findings be treated with caution.

In a controlled clinical study (Gusev et al., 1997; PMID 11517472), 30 stroke patients received Semax at 12 to 18 mg per day intranasally over 5 to 10 day courses alongside standard therapy, compared to 80 historical controls of analogous severity. Neurological recovery assessed by clinical rating scales, EEG mapping, and somatosensory evoked potentials was more rapid in the Semax group. A subsequent study (Gusev et al., 2005; PMID 15792140) enrolled 187 patients with chronic cerebrovascular insufficiency and reported disease stabilization and reduced incidence of transient ischemic attacks over follow-up, but again lacked a placebo control arm.

In animal models, daily Semax at 60 nmol/kg reversed anhedonia, attenuated adrenal gland enlargement, and normalized suppressed hippocampal BDNF in male rats subjected to chronic unpredictable stress (Inozemtseva et al., Eur J Pharmacol, 2024; PMID 39442746). A 2025 preclinical study in APP/PS1 Alzheimer's transgenic mice found that intranasal Semax at 50 mcg/kg every other day for one month reduced cortical amyloid plaque burden 2.8-fold at 7.5 months, with effects persisting at 1.5 months post-treatment (Dolotov et al., Acta Naturae, 2025; PMID 41479572).

No peer-reviewed human trial has examined low-dose Semax for sleep support or evening cognitive calming specifically. Claims for these applications are extrapolated from anxiolytic findings in stressed-animal models and remain anecdotal.

Typical dosage: 100-200 mcg (evening).

Russian approved clinical prescribing for stroke and cerebrovascular indications: intranasal 6 to 18 mg per day divided over two to three administrations, given in 5 to 10 day courses under medical supervision. These doses far exceed what is used in nootropic self-administration.

Community nootropic use (not grounded in clinical trials): typical intranasal dose of 200 to 600 mcg per administration, once or twice daily, using commercial 0.1% nasal spray solutions. Each actuation of a standard Russian-formulation spray delivers approximately 300 mcg. Low-dose protocols — frequently described as 100 to 250 mcg once daily — are reported as less activating and are occasionally taken in early evening by users seeking mild anxiolytic effects without stimulation. This pattern is purely anecdotal.

Subcutaneous injection at similar mass doses is also reported in nootropic communities, though human clinical data for this route at nootropic doses are absent.

Common cycling patterns: 10 to 14 days on followed by a 4 to 8 week rest interval. These cycling protocols are not supported by controlled data. The weight of community-reported experience places standard Semax dosing (300 mcg and above) in the morning only, as late-day administration is frequently associated with difficulty initiating sleep.

This information is educational in nature and does not constitute medical advice. Semax is not approved by the FDA or EMA and is not subject to pharmaceutical quality-control standards outside Russia and Ukraine.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most widely described combination is Semax with Selank, a related Russian neuropeptide registered as an anxiolytic in Russia. The proposed rationale treats Semax as a cognitive activator (BDNF upregulation, attention enhancement) and Selank as a cognitive stabilizer (allosteric GABA-A modulation, anxiolysis). Users anecdotally describe the pairing as producing "calm focus," with Selank moderating the mild overstimulation some experience from Semax alone. No controlled human or animal study has examined this combination directly; evidence is entirely anecdotal and community-sourced.

Semax is occasionally reported alongside BPC-157 based on overlapping neuroprotective rationales, and with racetam-class nootropics (piracetam, aniracetam) based on the proposed complementarity between AMPA receptor modulation and BDNF support. Both of these combinations are anecdotal only, without any supporting published research.

All combination strategies described here derive from nootropic community reports and vendor-sourced content, not controlled evidence.

Semax Low Dose is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed Semax Low Dose from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place Semax Low Dose on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated at low doses

Russian clinical trials in up to 187 patients receiving medical-dose Semax (6 to 18 mg/day intranasally) did not report serious adverse events. Investigators described the compound as well-tolerated including in older age groups. No preclinical studies have reported specific toxic reactions.

At nootropic intranasal doses, commonly reported effects are mild: • Nasal mucosal irritation, dryness, or transient burning • Altered sense of taste or smell, typically short-lived • Difficulty initiating sleep when dosed in the afternoon or evening, attributed to dose-dependent stimulant-like activity • Mild agitation or elevation of anxiety; a study with 16 healthy but fatigued subjects noted slight anxiety increase following a single 1 mg intranasal dose

One observational report noted mild blood glucose elevation in approximately 7.4% of diabetic patients using Semax, warranting caution in individuals with impaired glucose regulation.

Long-term safety data for self-administration use are absent. No carcinogenicity, reproductive toxicity, or genotoxicity studies have been published for the nootropic dose range.

Contraindications and precautions: • Known hypersensitivity to Semax or formulation excipients • Pregnancy and breastfeeding (no safety data exist) • Active severe anxiety disorders (stimulant-like effects may worsen symptoms) • Uncontrolled hypertension or cardiovascular instability • Hepatic or renal impairment (unstudied)

Semax is not scheduled in the United States or European Union but is not approved for therapeutic use outside Russia and Ukraine, and occupies a regulatory gray zone when sold as a research chemical.